Curtiss, Brittany M. http://orcid.org/0000-0002-5274-8323
VanCampen, Jake
Macaraeg, Jommel
Kong, Garth L. http://orcid.org/0000-0001-5262-5406
Taherinasab, Akram
Tsuchiya, Mitsuhiro
Yashar, William M. http://orcid.org/0000-0002-8850-9850
Tsang, Yiu H.
Horton, Wesley
Coleman, Daniel J.
Estabrook, Joseph
Lusardi, Theresa A.
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Maxson, Julia E. http://orcid.org/0000-0002-3871-7221
Braun, Theodore P. http://orcid.org/0000-0002-6248-2143
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1 K08 CA245224)
Article History
Received: 3 November 2021
Revised: 3 May 2022
Accepted: 5 May 2022
First Online: 19 May 2022
Competing interests
: BJD -- SAB: Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (SAB inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Founder: VB Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). J.E.M. -- SAB: Ionis pharmaceuticals. WMY -- former employee of Abreos Biosciences, Inc. and was compensated in part with common stock options. Pursuant to the merger and reorganization agreement between Abreos Biosciences, Inc. and Fimafeng, Inc., WMY surrendered all of his common stock options in 03/2021. The other authors do not have conflicts of interest, financial or otherwise.